Immage Financial Statements From 2010 to 2026

IMMG Stock  USD 0.0001  0.00  0.000003%   
Immage Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immage Biotherapeutics' valuation are provided below:
Market Capitalization
15.2 K
Earnings Share
(0.01)
There are over eighty-one available fundamental trends for Immage Biotherapeutics, which can be analyzed over time and compared to other ratios. Active traders should verify all of Immage Biotherapeutics regular fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The Immage Biotherapeutics' current Market Cap is estimated to increase to 137.31, while Working Capital is projected to decrease to (28.9 K).
Check Immage Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immage Biotherapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 186.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Immage financial statements analysis is a perfect complement when working with Immage Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Immage Stock
Check out the analysis of Immage Biotherapeutics Correlation against competitors.

Immage Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets293.5 K279.6 K182.8 K
Slightly volatile
Total Current Liabilities40.5 K64.2 K46.3 K
Slightly volatile
Accounts Payable2.6 K3.5 K2.6 K
Slightly volatile
Cash237.5 K226.2 K146.3 K
Slightly volatile
Total Liabilities40.5 K64.2 K46.3 K
Slightly volatile
Short and Long Term Debt612463624
Slightly volatile
Total Current Assets247.6 K235.8 K152.4 K
Slightly volatile
Common Stock108.8 K168.8 K117.9 K
Slightly volatile

Immage Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative186.3 K177.4 K118.8 K
Slightly volatile
Research Development49.8 K56 K61.1 K
Slightly volatile
Total Operating Expenses261.4 K248.9 K164 K
Slightly volatile

Immage Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock4.4 K4.2 K2.8 K
Slightly volatile
Net Borrowings5.3 K5.6 K8.6 K
Slightly volatile
Depreciation10.3 K9.8 K6.4 K
Slightly volatile
Total Cash From Financing Activities458.7 K436.8 K287.3 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.4 K1.4 K1.1 K
Slightly volatile
Capex To Depreciation43.0248.3952.8176
Slightly volatile
Payables Turnover2.242.522.7479
Slightly volatile
Cash Per Share0.00120.00120.0198
Pretty Stable
Days Payables Outstanding104117128
Slightly volatile
Income Quality1.091.1558.9919
Slightly volatile
Intangibles To Total Assets0.02290.02180.0169
Slightly volatile
Current Ratio3.473.312.5983
Slightly volatile
Capex Per Share4.0E-44.0E-44.0E-4
Slightly volatile
Interest Debt Per Share3.0E-43.0E-40.0279
Pretty Stable
Debt To Assets0.240.251.1201
Slightly volatile
Days Of Payables Outstanding104117128
Slightly volatile
Ebt Per Ebit8.0E-49.0E-40.001
Slightly volatile
Quick Ratio3.473.312.5983
Slightly volatile
Net Income Per E B T800900982
Slightly volatile
Cash Ratio3.333.172.5726
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.421.611.7525
Slightly volatile
Debt Ratio0.240.251.1201
Slightly volatile

Immage Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap137131102
Slightly volatile

About Immage Biotherapeutics Financial Statements

Immage Biotherapeutics stakeholders use historical fundamental indicators, such as Immage Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Immage Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immage Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Immage Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immage Biotherapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Currently Active Assets on Macroaxis

When determining whether Immage Biotherapeutics is a strong investment it is important to analyze Immage Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immage Biotherapeutics' future performance. For an informed investment choice regarding Immage Stock, refer to the following important reports:
Check out the analysis of Immage Biotherapeutics Correlation against competitors.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immage Biotherapeutics. If investors know Immage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immage Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(4.96)
Return On Equity
(11.34)
The market value of Immage Biotherapeutics is measured differently than its book value, which is the value of Immage that is recorded on the company's balance sheet. Investors also form their own opinion of Immage Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immage Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immage Biotherapeutics' market value can be influenced by many factors that don't directly affect Immage Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.